High frequency of clonal hematopoiesis in Erdheim-Chester disease
- 28 January 2021
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 137 (4), 485-492
- https://doi.org/10.1182/blood.2020005101
Abstract
Erdheim-Chester disease (ECD) is a clonal hematopoietic disorder characterized by the accumulation of foamy histiocytes within organs, in particular frequent retroperitoneal involvement, and a high frequency of BRAFV600E mutations. Although ECD is not commonly recognized to have overt peripheral blood (PB) or bone marrow (BM) disease, we recently identified that ECD patients have a high frequency of a concomitant myeloid malignancy. Given this finding and the fact that clonal hematopoiesis frequency precedes development of myeloid malignancies, we conducted a systematic clinical and molecular analysis of the BM from 120 ECD patients. Surprisingly, 42.5% (51/120) of ECD patients had clonal hematopoiesis while 15.8% (19/120) of patients developed an overt hematologic malignancy (nearly all of which were a myeloid neoplasm). The most frequently mutated genes in BM were TET2, ASXL1, DNMT3A, and NRAS. ECD patients with clonal hematopoiesis were more likely to be older (pBRAFV600E mutation (p=0.049) than those without clonal hematopoiesis. The presence of the TET2 mutation was associated with a BRAFV600E mutation in tissue ECD lesions (p=0.0006) and TET2 mutant ECD patients were more likely to have vascular involvement than TET2 wild-type ECD patients. Clonal hematopoiesis mutations in ECD were detected in cells derived from CD34+CD38- BM progenitors and PB monocytes but less frequently present in PB B- and T-lymphocytes. These data identify a heretofore unrecognized high frequency of clonal hematopoiesis in ECD patients, reaffirm the development of additional high risk of myeloid neoplasms in ECD, and provide evidence of a BM-based precursor cell-of-origin for many patients with ECD.This publication has 18 references indexed in Scilit:
- Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraBlood, 2020
- High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosisBlood, 2017
- Diverse and Targetable Kinase Alterations Drive Histiocytic NeoplasmsCancer Discovery, 2016
- The histiocytosis Erdheim–Chester disease is an inflammatory myeloid neoplasmExpert Review of Clinical Immunology, 2015
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromesBlood, 2015
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA SequenceThe New England Journal of Medicine, 2014
- Age-Related Clonal Hematopoiesis Associated with Adverse OutcomesThe New England Journal of Medicine, 2014
- Age-related mutations associated with clonal hematopoietic expansion and malignanciesNature Medicine, 2014
- Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseBlood, 2014
- High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosesBlood, 2012